The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study
Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2016-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2016/2909436 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562655476318208 |
|---|---|
| author | Matej Samoš Marián Fedor František Kovář Peter Galajda Tomáš Bolek Lucia Stančiaková Jana Fedorová Ján Staško Peter Kubisz Marián Mokáň |
| author_facet | Matej Samoš Marián Fedor František Kovář Peter Galajda Tomáš Bolek Lucia Stančiaková Jana Fedorová Ján Staško Peter Kubisz Marián Mokáň |
| author_sort | Matej Samoš |
| collection | DOAJ |
| description | Background. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67 patients were enrolled. 21 patients had T2D. Among all study population, 33 patients received clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor blocker therapy had been tested in two time intervals using light transmission aggregometry with specific inducer and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant differences in platelet aggregability among T2D and nondiabetic (ND) group. The platelet reactivity index of VASP-P did not differ significantly between T2D and ND group (59.4±30.9% versus 60.0±25.2% and 33.9±25.3% versus 38.6±29.3% in second testing). The number of ADP receptor blocker nonresponders did not differ significantly between T2D and ND patients. The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations. Conclusion. This prospective study did not confirm the higher platelet reactivity and higher prevalence of ADP receptor blocker nonresponders in T2D acute STEMI patients. |
| format | Article |
| id | doaj-art-11ead8647d6449a9807034a6e8624e97 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2016-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-11ead8647d6449a9807034a6e8624e972025-02-03T01:22:06ZengWileyJournal of Diabetes Research2314-67452314-67532016-01-01201610.1155/2016/29094362909436The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective StudyMatej Samoš0Marián Fedor1František Kovář2Peter Galajda3Tomáš Bolek4Lucia Stančiaková5Jana Fedorová6Ján Staško7Peter Kubisz8Marián Mokáň9Department of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaNational Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaNational Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaHemoMedika, Centre of Thrombosis and Hemostasis, 03601 Martin, SlovakiaNational Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaNational Centre of Hemostasis and Thrombosis, Department of Hematology and Blood Transfusion, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaDepartment of Internal Medicine I, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, 03659 Martin, SlovakiaBackground. The aim of this study was to validate the impact of type 2 diabetes (T2D) on the platelet reactivity in patients with acute ST elevation myocardial infarction (STEMI) treated with adenosine diphosphate (ADP) receptor blockers. Methods. A pilot prospective study was performed. Totally 67 patients were enrolled. 21 patients had T2D. Among all study population, 33 patients received clopidogrel and 34 patients received prasugrel. The efficacy of ADP receptor blocker therapy had been tested in two time intervals using light transmission aggregometry with specific inducer and vasodilator-stimulated phosphoprotein phosphorylation (VASP-P) flow cytometry assay. Results. There were no significant differences in platelet aggregability among T2D and nondiabetic (ND) group. The platelet reactivity index of VASP-P did not differ significantly between T2D and ND group (59.4±30.9% versus 60.0±25.2% and 33.9±25.3% versus 38.6±29.3% in second testing). The number of ADP receptor blocker nonresponders did not differ significantly between T2D and ND patients. The time interval from ADP receptor blocker loading dosing to the blood sampling was similar in T2D and ND patients in both examinations. Conclusion. This prospective study did not confirm the higher platelet reactivity and higher prevalence of ADP receptor blocker nonresponders in T2D acute STEMI patients.http://dx.doi.org/10.1155/2016/2909436 |
| spellingShingle | Matej Samoš Marián Fedor František Kovář Peter Galajda Tomáš Bolek Lucia Stančiaková Jana Fedorová Ján Staško Peter Kubisz Marián Mokáň The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study Journal of Diabetes Research |
| title | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
| title_full | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
| title_fullStr | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
| title_full_unstemmed | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
| title_short | The Impact of Type 2 Diabetes on the Efficacy of ADP Receptor Blockers in Patients with Acute ST Elevation Myocardial Infarction: A Pilot Prospective Study |
| title_sort | impact of type 2 diabetes on the efficacy of adp receptor blockers in patients with acute st elevation myocardial infarction a pilot prospective study |
| url | http://dx.doi.org/10.1155/2016/2909436 |
| work_keys_str_mv | AT matejsamos theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT marianfedor theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT frantisekkovar theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT petergalajda theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT tomasbolek theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT luciastanciakova theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT janafedorova theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT janstasko theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT peterkubisz theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT marianmokan theimpactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT matejsamos impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT marianfedor impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT frantisekkovar impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT petergalajda impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT tomasbolek impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT luciastanciakova impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT janafedorova impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT janstasko impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT peterkubisz impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy AT marianmokan impactoftype2diabetesontheefficacyofadpreceptorblockersinpatientswithacutestelevationmyocardialinfarctionapilotprospectivestudy |